Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 189

The DOI matches its Crossref record.

Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial

Open access
Hawkey, Christopher J., Allez, Matthieu, Clark, Miranda M., Labopin, Myriam, Lindsay, James O., Ricart, Elena, Rogler, Gerhard, Rovira, Montserrat, Satsangi, Jack, Danese, Silvio, Russell, Nigel, Gribben, John, Johnson, Peter, Larghero, Jerome, Thieblemont, Catherine, Ardizzone, Sandro, Dierickx, Daan, Ibatici, Adalberto, Littlewood, Timothy, Onida, Francesco, Schanz, Urs, Vermeire, Severine, Colombel, Jean-Frederic, Jouet, Jean-Paul, Clark, Elizabeth, Saccardi, Riccardo, Tyndall, Alan, Travis, Simon, Farge, Dominique · 2015 · JAMA

Abstract

IMPORTANCE: Case reports and series suggest hematopoietic stem cell transplantation (HSCT) may benefit some patients with Crohn disease. OBJECTIVE: To evaluate the effect of autologous HSCT on refractory Crohn disease. DESIGN, SETTING, AND PARTICIPANTS: Parallel-group randomized clinical trial conducted in 11 European transplant units from July 2007 to September 2011, with follow-up through March 2013. Patients were aged 18 to 50 years with impaired quality of life from refractory Crohn disease not amenable to surgery despite treatment with 3 or more immunosuppressive or biologic agents and corticosteroids. INTERVENTIONS: All patients underwent stem cell mobilization before 1:1 randomization to immunoablation and HSCT (n = 23) or control treatment (HSCT deferred for 1 year [n = 22]). All were given standard Crohn disease treatment as needed. MAIN OUTCOMES AND MEASURES: Sustained disease remission at 1 year, a composite primary end point comprising clinical remission (Crohn Disease Activity Index (CDAI) <150 [range, 0-600]), no use of corticosteroids or immunosuppressive or biologic drugs for at least the last 3 months, and no endoscopic or radiological evidence of active (erosive) disease anywhere in the gastrointestinal (GI) tract. Secondary outcomes were individual components of the primary composite outcome and other measures of disease activity, laboratory results, quality of life and functional status, and GI tract imaging. RESULTS: Twenty-three patients underwent HSCT and 22 received standard Crohn disease treatment (controls). Sustained disease remission was achieved in 2 patients undergoing HSCT (8.7%) vs 1 control patient (4.5%) (absolute difference, 4.2% [95% CI, -14.2% to 22.6%]; P = .60). Fourteen patients undergoing HSCT (61%) vs 5 control patients (23%) had discontinued immunosuppressive or biologic agents or corticosteroids for at least 3 months (difference, 38.1% [95% CI, 9.3% to 59.3%]; P = .01). Ten vs 2 patients had a CDAI less than 150 (remission) at the final evaluation, 8 (34.8%) vs 2 (9.1%) for 3 or more months (difference, 25.7% [95% CI, 1.1% to 47.1%]; P = .052). Eight (34.8%) vs 2 (9.1%) patients were adjudicated free of active disease on endoscopy and radiology at final assessment (difference, 25.7% [95% CI, 1.1% to 47.1%]; P = .054). There were 76 serious adverse events in patients undergoing HSCT vs 38 in controls. One patient undergoing HSCT died. CONCLUSIONS AND RELEVANCE: Among adult patients with refractory Crohn disease not amenable to surgery who had impaired quality of life, HSCT, compared with conventional therapy, did not result in a statistically significant improvement in sustained disease remission at 1 year and was associated with significant toxicity. These findings do not support the widespread use of HSCT for patients with refractory Crohn disease. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00297193.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2015.16700

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 189

Metadata

Authors
Hawkey, C. J., Allez, M., Clark, M. M., Labopin, M., Lindsay, J. O., Ricart, E., Rogler, G., Rovira, M., Satsangi, J., Danese, S., Russell, N., Gribben, J., Johnson, P., Larghero, J., Thieblemont, C., Ardizzone, S., Dierickx, D., Ibatici, A., Littlewood, T., Onida, F., Schanz, U., Vermeire, S., Colombel, J.-F., Jouet, J.-P., Clark, E., Saccardi, R., Tyndall, A., Travis, S., & Farge, D.
Venue
JAMA
Published
2015-12-15
Volume
314
Issue
23
Pages
2524
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W2202486845
Cited by
189
References
0
FWCI
14.80
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2015.16700
The paper
Hawkey, C. J., Allez, M., Clark, M. M., Labopin, M., Lindsay, J. O., Ricart, E., Rogler, G., Rovira, M., Satsangi, J., Danese, S., Russell, N., Gribben, J., Johnson, P., Larghero, J., Thieblemont, C., Ardizzone, S., Dierickx, D., Ibatici, A., Littlewood, T., . . . Farge, D. (2015). Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2015.16700

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.